Immunicon this week announced that it has signed a laboratory services and biomarker assay development pact with Merck Serono, the Geneva-based unit of Germany’s Merck KGaA.
 
Under the deal, Immunicon will develop specialized biomarker assays based on circulating tumor cells for an early clinical drug study. Immunicon said the new assays could potentially help doctors identify patients who have a high probability of responding to the drug being developed by Merck Serono.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.